Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424955 · ClinicalTrials.gov registry record · NA
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02424955: Completed NA study, sponsored by Stanford University.
NCT02424955 is a NA study that has completed, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02424955, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Interventions
- DRUG perflutren lipid microspheres
- DIAGNOSTIC_TEST 3D ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02424955
The ClinicalTrials.gov registry entry for NCT02424955 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which perflutren lipid microspheres is the first listed.
NCT02424955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02424955 about?
NCT02424955 is a clinical study titled "Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation". The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
What is the current status of trial NCT02424955?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2014-11-18. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02424955?
The interventions under investigation include: perflutren lipid microspheres (DRUG), 3D ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02424955?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.